Effect of Sitagliptin on glycemic profiles and their correlation with PASI score in patients with plaque psoriasis

Abstract

Psoriatic patients with plaque psoriasis particularly those with high body mass index have increasing risk of developing a diabetes mellitus type 2 (DM). Since both conditions are associated with dysregulation in DPP-IV, DPP-IV inhibitors have been suggested as therapeutic drugs for both diseases. The role of enzyme in the diabetes pathogenesis is well-known; however information on psoriatic patients is conflicting. The objective of this study is to determine the effect of Sitagliptin on glycemic profiles and their correlation with PASI score in psoriatic patients with DM. The study was conducted on 50 diabetic patients with moderate to severe plaque psoriasis who were divided into two groups: Placebo group (n =25) Patients were administered placebo 100mg once daily plus dietary control and exercise for 3 months ; Sitagliptin group (n =25) Patients were administered Sitagliptin tablet 100mg once a day plus dietary control and exercise for 3 month. PASI score for all patients was assessed before and after 12 weeks of treatment. The blood samples were obtained from the patients in both groups at baseline and after 12 week of therapy were used to measure the concentration of serum fasting blood sugar and HbA1c. Compared with baseline in Sitagliptin group and control group after 12 week, the level of fasting blood sugar, HbA1c, were significantly reduced and correlated with PASI score after 12 week of sitagliptin treatment (P < 0.05). The current results reveal that sitagliptin improves psoriasis possibly via a reduction in glycemic profiles which were significantly correlated with PASI score.

Effect of Different Types of Hypoglycemic Medications on Psoriasis: An Analysis of Current Evidence

“…The meta-analysis involved 18 clinical trials (Table 1) that treated patients using four types of hypoglycemic medicines: four trials used GLP-1 RAs [16][17][18][19], four used DPP-4 inhibitors [20][21][22][23], ten used TZDs [24][25][26][27][28][29][30][31], and two used biguanides [32,33]. Two trials [32,33] used TZDs and biguanides as parallel controls.…”

“…Data from 262 patients with psoriasis treated with hypoglycemic medicines and 278 patients with placebo or other systemic treatments were assessed to determine the changes in the PASI score [16,20,21,[23][24][25][26][27]29]. Shafip, 2005 [30], included two doses of 15 and 30 mg, and Abidi, 2020 [24], included two experimental groups in determining whether MTX should be used in combination.…”